Table 2.

Secondary resistance mutation patterns associated with N155H

Associated secondary mutationsa	Effects on drug resistance or viral fitness of N155 mutant
V72I40
V72I + E92G40
L74M + E92Q + V151I + E157Q72
E92Q/A/G36,42,45,75–77,79	Increases raltegravir and elvitegravir resistance
E92Q + T97A75	Increases raltegravir resistance compared to addition of E92Q alone
E92A + G163R45
Q95K37	Increases raltegravir and elvitegravir resistance; increases viral fitness
Q95K + V151I37	Increases raltegravir and elvitegravir resistance compared to addition of Q95K alone
T97A40,75	Increases raltegravir and elvitegravir resistance; increases viral fitness
T97A + V125A + V151I40	Increases raltegravir resistance compared to addition of V125A + V151I
T97A + V151I40,45	Increases raltegravir resistance compared to addition of T79A alone
T124A + V151I33,56
V125A + V151I40
G140S45
G140S + Q148H40,77,79
Y143R/H40,75,77,79	Increases raltegravir resistance
Y143R + E170A79
Q148R/H45,77
Q148H + E170A79
V151I33,38,45,53,56,75	Increases raltegravir resistance
V151I + M154I78
V151I + G163R45,53
M154I53,78
G163R/K45,75,76	Increases raltegravir and elvitegravir resistance; increases viral fitness
I204T33,56
D232N75

Notes:

^aShown are mutation patterns found in the same viral sample during in vitro or in vivo selection using raltegravir or elvitegravir. Mutations present at baseline or containing mixtures by population-based sequencing were excluded. References are given for each pattern of resistance mutations.